Los Angeles Capital Management LLC Has $636,000 Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Los Angeles Capital Management LLC cut its position in Insmed Incorporated (NASDAQ:INSM) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,205 shares of the biopharmaceutical company’s stock after selling 974 shares during the period. Los Angeles Capital Management LLC’s holdings in Insmed were worth $636,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. CIBC Asset Management Inc raised its holdings in Insmed by 3.5% in the third quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 149 shares during the period. Abel Hall LLC raised its holdings in Insmed by 4.7% in the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 151 shares during the period. Commerce Bank raised its holdings in Insmed by 2.4% in the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 163 shares during the period. Nisa Investment Advisors LLC raised its holdings in Insmed by 5.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 183 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Insmed by 3.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock worth $446,000 after acquiring an additional 186 shares during the period.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 33,055 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total value of $2,674,149.50. Following the transaction, the insider now owns 138,053 shares in the company, valued at approximately $11,168,487.70. This represents a 19.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the completion of the transaction, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,912,553.60. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 532,207 shares of company stock worth $41,400,465. Insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on INSM. Wells Fargo & Company raised their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Stifel Nicolaus dropped their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, Guggenheim reiterated a “buy” rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.60.

Insmed Stock Up 3.2 %

Insmed stock opened at $81.55 on Monday. The firm has a market capitalization of $14.76 billion, a PE ratio of -14.59 and a beta of 1.11. The company’s 50-day moving average is $75.08 and its 200-day moving average is $73.80. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Sell-side analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.